Isabel Karen Temple

Isabel Karen Temple

Auto-generated profile, based on publicly available information

Isabel Karen Temple

Faculty of Medicine, University of Southampton, Southampton, UK

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
AGAnna Gloyn
Anna Gloyn
EPEwan R. Pearson
Ewan R. Pearson
JAJennifer F. Antcliff
Jennifer F. Antcliff
PPPeter Proks
Peter Proks
GBG. Jan Bruining
G. Jan Bruining
AHAndrew T. Hattersley
Andrew T. Hattersley
Patients with permanent neonatal diabetes usually present within the first three months of life and require insulin treatment. In most, the cause is unknown. Because ATP-sensitive potassium (KATP) channels mediate glucose-stimulated insulin secretion from the pancreatic beta cells, we hypothesized that activating mutations in the gene encoding the Kir6.2 subunit of this channel (KCNJ11) cause neonatal diabetes.

11 July 2008 in Nature Genetics
Verified
Journal Article
Closed access
DMDeborah J G Mackay
Deborah J G Mackay
JCJonathan L A Callaway
Jonathan L A Callaway
SMSophie M Marks
Sophie M Marks
HWHelen E White
Helen E White
CACarlo L Acerini
Carlo L Acerini
ITI Karen Temple
I Karen Temple

2 September 2016 in Nature Reviews Endocrinology
Verified
Journal Article
Open access
PDF file
EWEmma L. Wakeling
Emma L. Wakeling
FBFrédéric Brioude
Frédéric Brioude
OLOluwakemi Lokulo-Sodipe
Oluwakemi Lokulo-Sodipe
SOSusan M. O'Connell
Susan M. O'Connell
JSJennifer Salem
Jennifer Salem
INIrène NETCHINE
Irène NETCHINE
This Consensus Statement summarizes recommendations for clinical diagnosis, investigation and management of patients with Silver–Russell syndrome (SRS), an imprinting disorder that causes prenatal and postnatal growth retardation. Considerable overlap exists between the care of individuals born small for gestational age and those with SRS. However, many specific management issues exist and evidence from controlled trials remains limited. SRS is primarily a clinical diagnosis; however, molecular testing enables confirmation of the clinical diagnosis and defines the subtype. A 'normal' result from a molecular test does not exclude the diagnosis of SRS. The management of children with SRS requires an experienced, multidisciplinary approach. Specific issues include growth failure, severe feeding difficulties, gastrointestinal problems, hypoglycaemia, body asymmetry, scoliosis, motor and speech delay and psychosocial challenges. An early emphasis on adequate nutritional status is important, with awareness that rapid postnatal weight gain might lead to subsequent increased risk of metabolic disorders. The benefits of treating patients with SRS with growth hormone include improved body composition, motor development and appetite, reduced risk of hypoglycaemia and increased height. Clinicians should be aware of possible premature adrenarche, fairly early and rapid central puberty and insulin resistance. Treatment with gonadotropin-releasing hormone analogues can delay progression of central puberty and preserve adult height potential. Long-term follow up is essential to determine the natural history and optimal management in adulthood.

22 February 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SBSabina Benko
Sabina Benko
JFJudy A Fantes
Judy A Fantes
JAJeanne Amiel
Jeanne Amiel
DKDirk-Jan Kleinjan
Dirk-Jan Kleinjan
Sophie ThomasSophie Thomas
Sophie Thomas
SLStanislas Lyonnet
Stanislas Lyonnet

9 March 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CCChildhood Overgrowth Consortium
Childhood Overgrowth Consortium
KTKatrina Tatton-Brown
Katrina Tatton-Brown
SSSheila Seal
Sheila Seal
ERElise Ruark
Elise Ruark
JHJenny Harmer
Jenny Harmer
NRNazneen Rahman
Nazneen Rahman
Nazneen Rahman, Katrina Tatton-Brown and colleagues identify de novo mutations in the DNA methyltransferase gene DNMT3A as the cause of a new overgrowth syndrome. Shared features of this syndrome include a distinctive facial appearance, intellectual disability and greater height. Overgrowth disorders are a heterogeneous group of conditions characterized by increased growth parameters and other variable clinical features such as intellectual disability and facial dysmorphism1. To identify new causes of human overgrowth, we performed exome sequencing in ten proband-parent trios and detected two de novo DNMT3A mutations. We identified 11 additional de novo mutations by sequencing DNMT3A in a further 142 individuals with overgrowth. The mutations alter residues in functional DNMT3A domains, and protein modeling suggests that they interfere with domain-domain interactions and histone binding. Similar mutations were not present in 1,000 UK population controls (13/152 cases versus 0/1,000 controls; P < 0.0001). Mutation carriers had a distinctive facial appearance, intellectual disability and greater height. DNMT3A encodes a DNA methyltransferase essential for establishing methylation during embryogenesis and is commonly somatically mutated in acute myeloid leukemia2,3,4. Thus, DNMT3A joins an emerging group of epigenetic DNA- and histone-modifying genes associated with both developmental growth disorders and hematological malignancies5.

1 September 2015 in The Lancet
Verified
Journal Article
Open access
EFElisa De Franco
Elisa De Franco
SFSarah Flanagan
Sarah Flanagan
JHJayne AL Houghton
Jayne AL Houghton
HAHana Lango Allen
Hana Lango Allen
DMDeborah Jg Mackay
Deborah Jg Mackay
AHAndrew T Hattersley
Andrew T Hattersley
Traditional genetic testing focusses on analysis of one or a few genes according to clinical features; this approach is changing as improved sequencing methods enable simultaneous analysis of several genes. Neonatal diabetes is the presenting feature of many discrete clinical phenotypes defined by different genetic causes. Genetic subtype defines treatment, with improved glycaemic control on sulfonylurea treatment for most patients with potassium channel mutations. We investigated the effect of early, comprehensive testing of all known genetic causes of neonatal diabetes. In this large, international, cohort study, we studied patients with neonatal diabetes diagnosed with diabetes before 6 months of age who were referred from 79 countries. We identified mutations by comprehensive genetic testing including Sanger sequencing, 6q24 methylation analysis, and targeted next-generation sequencing of all known neonatal diabetes genes. Between January, 2000, and August, 2013, genetic testing was done in 1020 patients (571 boys, 449 girls). Mutations in the potassium channel genes were the most common cause (n=390) of neonatal diabetes, but were identified less frequently in consanguineous families (12% in consanguineous families vs 46% in non-consanguineous families; p4 years; p<0·0001), in whom skeletal and liver involvement was common. Similarly, for patients with genetically diagnosed transient neonatal diabetes, the diabetes had remitted in only ten (10%) of 101 patients tested early (<3 months) compared with 60 (100%) of the 60 later referrals (p<0·0001). Patients are now referred for genetic testing closer to their presentation with neonatal diabetes. Comprehensive testing of all causes identified causal mutations in more than 80% of cases. The genetic result predicts the best diabetes treatment and development of related features. This model represents a new framework for clinical care with genetic diagnosis preceding development of clinical features and guiding clinical management. Wellcome Trust and Diabetes UK.